CN116920049A - Skin-care oil for treating gastric ulcer and preparation method and application thereof - Google Patents
Skin-care oil for treating gastric ulcer and preparation method and application thereof Download PDFInfo
- Publication number
- CN116920049A CN116920049A CN202310849834.9A CN202310849834A CN116920049A CN 116920049 A CN116920049 A CN 116920049A CN 202310849834 A CN202310849834 A CN 202310849834A CN 116920049 A CN116920049 A CN 116920049A
- Authority
- CN
- China
- Prior art keywords
- parts
- oil
- gastric
- skin
- gastric ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 160
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 128
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000003921 oil Substances 0.000 claims abstract description 109
- 235000019198 oils Nutrition 0.000 claims abstract description 107
- 239000003814 drug Substances 0.000 claims abstract description 99
- 230000002496 gastric effect Effects 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 17
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 15
- 230000007613 environmental effect Effects 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 14
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 14
- 229940116229 borneol Drugs 0.000 claims abstract description 14
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 14
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000004863 Frankincense Substances 0.000 claims abstract description 12
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 12
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 12
- 230000001154 acute effect Effects 0.000 claims abstract description 12
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 11
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 11
- 241001313857 Bletilla striata Species 0.000 claims abstract description 10
- 235000006533 astragalus Nutrition 0.000 claims abstract description 10
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 9
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 9
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 9
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 9
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims abstract description 9
- 240000004980 Rheum officinale Species 0.000 claims abstract description 9
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 7
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 7
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 6
- 240000004064 Poterium sanguisorba Species 0.000 claims abstract 4
- 230000002829 reductive effect Effects 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 239000008159 sesame oil Substances 0.000 claims description 10
- 235000011803 sesame oil Nutrition 0.000 claims description 10
- 239000003240 coconut oil Substances 0.000 claims description 9
- 235000019864 coconut oil Nutrition 0.000 claims description 9
- 241000972673 Phellodendron amurense Species 0.000 claims description 7
- 244000061520 Angelica archangelica Species 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 6
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 241000405414 Rehmannia Species 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241001061264 Astragalus Species 0.000 claims description 3
- 241000717739 Boswellia sacra Species 0.000 claims description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 3
- 238000003304 gavage Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 210000004233 talus Anatomy 0.000 claims description 3
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 230000001473 noxious effect Effects 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 238000010008 shearing Methods 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 244000247747 Coptis groenlandica Species 0.000 claims 1
- 230000036560 skin regeneration Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 60
- 206010030113 Oedema Diseases 0.000 abstract description 42
- 230000000740 bleeding effect Effects 0.000 abstract description 32
- 230000030136 gastric emptying Effects 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 21
- 208000027418 Wounds and injury Diseases 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 7
- 238000010186 staining Methods 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 119
- 210000001156 gastric mucosa Anatomy 0.000 description 68
- 210000002784 stomach Anatomy 0.000 description 60
- 210000004877 mucosa Anatomy 0.000 description 36
- 208000025865 Ulcer Diseases 0.000 description 35
- 239000010410 layer Substances 0.000 description 34
- 231100000397 ulcer Toxicity 0.000 description 33
- 208000032843 Hemorrhage Diseases 0.000 description 31
- 208000034158 bleeding Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 210000004969 inflammatory cell Anatomy 0.000 description 21
- 230000008595 infiltration Effects 0.000 description 19
- 238000001764 infiltration Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 238000002648 combination therapy Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000001575 pathological effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 239000006187 pill Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 230000002159 abnormal effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000007547 defect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000000877 morphologic effect Effects 0.000 description 9
- 210000005081 epithelial layer Anatomy 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 208000027744 congestion Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000003628 erosive effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000030135 gastric motility Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229960004157 rabeprazole Drugs 0.000 description 6
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 244000173853 Sanguisorba officinalis Species 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960002626 clarithromycin Drugs 0.000 description 4
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 210000001711 oxyntic cell Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229960005053 tinidazole Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- ZGDLVKWIZHHWIR-UHFFFAOYSA-N 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N2CCOCC2)N=C1 ZGDLVKWIZHHWIR-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 206010019375 Helicobacter infections Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229960001778 rabeprazole sodium Drugs 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241001313855 Bletilla Species 0.000 description 2
- 241000218202 Coptis Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010017788 Gastric haemorrhage Diseases 0.000 description 2
- 206010017815 Gastric perforation Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 241000581682 Sanguisorba Species 0.000 description 2
- 241000519995 Stachys sylvatica Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KKMOSYLWYLMHAL-UHFFFAOYSA-N 2-bromo-6-nitroaniline Chemical compound NC1=C(Br)C=CC=C1[N+]([O-])=O KKMOSYLWYLMHAL-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010017826 Gastric ulcer haemorrhage Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101150056637 Hrh2 gene Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- UJOHNXQDVUADCG-UHFFFAOYSA-L aluminum;magnesium;carbonate Chemical compound [Mg+2].[Al+3].[O-]C([O-])=O UJOHNXQDVUADCG-UHFFFAOYSA-L 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000012335 pathological evaluation Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of new indications of medicines, and particularly discloses skin-care oil for treating gastric ulcer and a preparation method and application thereof. The raw materials of the composition are as follows: 30-50 parts of astragalus membranaceus, 30-50 parts of angelica sinensis, 30-50 parts of garden burnet, 10-30 parts of bletilla striata, 10-30 parts of frankincense, 5-10 parts of radix scutellariae, 5-10 parts of coptis chinensis, 5-10 parts of rheum officinale, 5-10 parts of cortex phellodendri, 5-10 parts of rehmannia glutinosa, 5-10 parts of gynura procumbens, 10-15 parts of borneol and 1000-1500 parts of edible vegetable oil, and heating in batches, and mixing to prepare the oral skin care oil. Hematoxylin-eosin (HE) staining results show that gastric administration of the skin-care oil can reduce bleeding area, reduce gastric emptying rate, eliminate inflammatory reaction, quickly repair gastric ulcer wound surfaces, protect gastric tissue morphology and structure, and effectively treat gastric ulcers including alcoholic acute gastric ulcers, non-steroidal anti-inflammatory drug gastric ulcers and environmental cold-stimulated acute gastric ulcers by controlling mucosal congestion and edema at gastric ulcer sites.
Description
Technical Field
The invention relates to the technical field of new indications of medicines, in particular to skin oil for treating gastric ulcer and a preparation method and application thereof.
Background
The integrity of the gastric mucosal epithelium, mucosal cell turnover, epidermal growth factor, mucus-bicarbonate barrier, mucosal blood flow, prostaglandins, etc. form the defensive barrier of the gastric mucosa. Once helicobacter pylori infection, stress, medicines and other factors (such as binge eating, overfatigue and the like) and the like cause unbalance of an attacking factor of ulcer and a defending factor for protecting gastric mucosa, the gastric mucosa is broken under the attack of gastric acid and the like, and wounds reach submucosa even deeper, so that the inner side of the gastric wall presents a sunken pathological change state, namely gastric ulcer. The main clinical signs of the traditional Chinese medicine can be upper abdominal pain, abdominal distension, nausea, acid regurgitation, vomiting and the like, and the serious symptoms can cause perforation and gastrointestinal bleeding, thus endangering the life of patients.
Gastric ulcers are a common, recurrent and worldwide distributed disease. Clinical manifestations of gastric ulcers, while typical symptoms of chronic, periodic, rhythmic, postprandial abdominal pain are predominant, often result in attacks by different causes. And the complications can be classified into mild and severe complications according to the severe complications such as anemia, gastric perforation, gastrorrhagia, pyloric obstruction, etc. For light gastric ulcers, in clinic, tetrad therapy is generally considered, and proton pump inhibitors (omeprazole, rabeprazole, etc.) plus two antibiotics (clarithromycin, amoxicillin, tinidazole, levofloxacin, etc.), as well as H2 receptor inhibitors that inhibit gastric acid and a protective agent that protects gastric mucosa (bismuth pectin, bismuth subcarbonate, magnesium aluminum carbonate, bismuth potassium citrate, etc.), are used under the direction of a specialist for several weeks. If symptoms such as abdominal pain and anemia are serious or ulcers are large, symptoms such as bleeding are accompanied, it is necessary to take a plurality of days to eat and perform drip treatment, and to perform treatment of stopping bleeding, even blood transfusion and iron intake. Once the helicobacter pylori infection is diagnosed, it is also necessary to perform simultaneous sterilization treatment. When severe emergency such as hemostasis difficulty and gastric perforation is encountered, surgical treatment is required. In short term, western medicines have obvious curative effect, but after long-term administration of the medicines, the medicines are easy to generate drug resistance of antibiotics, even adverse reactions (including nausea, diarrhea, pseudomembranous enteritis and the like) occur frequently, and even toxic and side effects are caused, so that subsequent treatment is difficult, and finally, the illness state is repeated, and the lasting difficulty is cured.
However, a specific medicine with obvious curative effect, convenient use and no toxic or side effect is still lacking clinically. Therefore, the search for specific medicines for treating gastric ulcer from traditional Chinese medicines becomes the focus of attention of many medical students and is also the main object of the invention.
The research content of the invention is supported by the project ' beta-catenin/COX-2 inflammatory loop based ' on foundation of national natural scientist in 2021 ' on the foundation of the research on the effect mechanism (2022.1-2025.12) of external skin oil for promoting rapid repair of diabetic foot disease.
Disclosure of Invention
Aiming at the problem that the prior art lacks specific medicines for treating gastric ulcer:
a first object of the present invention is to provide a stomach-lavage skin-generating oil effective for treating gastric ulcer.
The second aim of the invention is to provide a preparation method of the stomach-lavage skin-care oil for treating gastric ulcer.
The third object of the invention is to provide the medical application of the stomach-lavage skin-care oil for treating gastric ulcer. The inventive concept of the present invention is as follows:
the people's knowledge on gastric ulcer is that gastric acid secretion is initially inhibited until the protection effect of the whole gastric mucosa barrier is emphasized, and the therapeutic medicine is also regulated from the original weak base medicine to the application of the existing proton pump inhibitor and antibiotics. At present, a combined therapy for protecting gastric mucosa and inhibiting gastric acid secretion is adopted, but the combined therapy is still limited by the problems of side effects of compound medicines, high recurrence rate (natural recurrence rate of 1 year is up to 60% -80%), and the like, and the problem of drug resistance caused by antibiotics.
Although there is no disease name of gastric ulcer in the theory of traditional Chinese medicine in China, according to clinical symptoms, the disease belongs to the categories of epigastric pain, gastric abscess and acid regurgitation. The etiology and pathogenesis of the disease can be divided into: (1) exogenous pathogenic factors affecting the stomach. That is, the pathogenic factors such as exogenous wind, cold, dampness and heat cause epigastric pain. "Huangdi's internal channel-Su ■ pain-relieving theory" is: the cold is absorbed in the intestines and stomach, under the membrane, blood can not be dispersed, and small collaterals lead to acute pain; (2) the diet hurts the stomach. The spleen and stomach are incoordination, i.e. too much diet, no dissimilation and hurt in the gastric cavity, caused by the lack of understanding of food intake, supercooling, raw food or short-time sudden increase of diet; (3) internal injury due to seven emotions. "spleen and stomach theory" is: happiness, anger, anxiety and terrorism, and loss of primordial qi. Depression and anger, emotional disturbance can cause liver failure and diarrhea, and transverse adverse qi affecting the stomach, resulting in obstruction of qi flow of the spleen and stomach and epigastralgia. The unsmooth emotion can directly interfere the middle-jiao qi movement, damage the interior of the middle-jiao qi and cause the spleen and stomach to float in a deficient way so as to cause diseases; (4) blood stasis blocks collaterals. Mainly relates to long-term non-healing or recurrence, the patients mostly have symptoms of liver depression, qi stagnation and blood stasis, the patients consider the disease to be the root of the disease by the doctor, the appearance is the exterior of the disease by toxin, and the stasis is the root of the disease; (5) spleen and stomach weakness. Modern doctor Wang Jianhua considers that the disease foundation of gastric ulcer is spleen deficiency, which is unified with the concept that spleen and stomach qi is not injured to nourish primordial qi, spleen and stomach injury causes primordial qi not to be full, which is mentioned in ancient books, theory of spleen and stomach deficiency and excess transfer theory.
In general, gastric ulcer is caused by excessive exogenous pathogenic factors in the early stage and caused by deficiency of spleen and stomach in the later stage, so the treatment principle is mainly considered to strengthen spleen, regulate qi, harmonize stomach and relieve pain. Therefore, the treatment is usually based on differentiation of symptoms and signs.
However, the traditional Chinese medicine composition is very regrettably, no matter Western medicine or traditional Chinese medicine treatment means are adopted, and a specific medicine which has obvious and rapid curative effect, convenient use and no toxic or side effect is still lacking clinically at present. Therefore, active searching for effective medicines for treating gastric ulcers, especially gastric ulcers caused by different causes, is an important point of attention for many pharmaceutical scientists, and is also a main object of the present application.
Previous researches of the inventor prove that the stomach-perfusing skin-growing oil in CN109939182A 'the application of the skin-growing oil for treating ulcerative colitis in preparation of medicines for treating ulcerative colitis' can effectively treat mild and severe ulcerative colitis by controlling inflammatory reaction at an ulcer part, protecting ulcer wound surfaces and maintaining tissue morphological structures at the ulcer part.Ulcerative colon Although inflammation and gastric ulcer have a common pathological link, namely, the mucosal barrier is broken, the stomach is strongly acidic, and the intestinal tract is internally provided with a protective layer Is alkaline and the root causes of both ulcerative colitis and gastric ulcer formation are quite different. Root cause of gastric ulcer formation Due to drugs (including non-steroidal anti-inflammatory drugs, glucocorticoids, chemotherapeutics, etc.), gastric emptying disorders (food in Gastric retention, abnormal fermentation, acid production and gas production; the food with dyspepsia can be decomposed by bacteria in intestinal cavity to generate a large amount of air Body, thereby aggravating abdominal distention), helicobacter pylori infection, etc., and its causes include alcoholism, overeating, etc. Ulcerative colon Inflammation is caused by the interaction of environmental factors, genetics, intestinal microecology, immunity and other factors; and the pH value of the intestinal tract is completely different from that of the intestinal tract The acidic environment of the stomach is alkaline. Based on the knowledge of the influence of pH value on the drug action in pharmacology, the composition can be developed in alkaline environment The skin-care oil with good therapeutic effect can not be ensured to develop after the pH value of the administration part is reversed to be acidic Has good therapeutic effect. Furthermore, the applicant forms the research thought of the application based on the cognition of the historic doctors on the pathogenesis of gastric ulcer and combined with the long-term traditional Chinese medicine pharmacology research of skin oil: firstly, gastric acid inhibiting medicines are used for protecting the ulcer surface from being damaged (the baical skullcap root in the skin oil can play the role); secondly, the ulcer surface is protected by using a viscous medicine (the bletilla striata and sesame oil in the skin oil can play the role); thirdly, the medicine for invigorating qi and promoting tissue regeneration is used for enhancing local injury resistance and repair capability (Astragalus mongholicus can play the role in skin oil); fourthly, adopting a medicament for promoting blood circulation to remove blood stasis, improving local microcirculation and providing good conditions for repairing wound surfaces (angelica in skin oil can play the role); fifthly, the medicine for detoxication and eliminating evil is utilized to kill helicobacter pylori and prevent further deterioration (coptis and rhubarb can play the role).
Although CN109939182a "an application of the skin oil for treating ulcerative colitis in preparing a medicament for treating ulcerative colitis" contains five kinds of medicaments for eliminating the cause of gastric ulcer, which are possible to improve gastric ulcer, because the administration position is reversed in pH value, the inventor must combine the effects of traditional Chinese medicine on the differentiation of gastric ulcer and the pH value in pharmacology on the medicament action, add and subtract the prior art of the skin oil for treating ulcerative colitis to form a new prescription, so as to simulate gastric ulcer caused by various most common clinical factors (such as alcohol, non-steroidal anti-inflammatory drugs and environmental factors), adopt a rat model of corresponding gastric ulcer, and adopt different Chinese patent medicine controls (alcohol-spleen and stomach damp-heat type-Sanjiutoy particles; non-steroidal anti-inflammatory drugs-spleen and stomach cold type-small building particles; environment cold stimulus-exogenous cold type-good attaching pills) under the Chinese medicine classification, and explore whether the skin oil has the effect of treating gastric ulcer. Based on a large number of scientific experimental researches, the application proves that when the skin oil prepared by the application is used, the gastric lavage administration can effectively treat and control the mucosal congestion and edema of gastric ulcer parts, reduce the bleeding area, reduce the gastric emptying rate, eliminate inflammatory reaction, quickly repair gastric ulcer wound surfaces and protect the morphological structure of gastric tissues. In other words, the oral administration of the skin-care oil can effectively improve gastric ulcers caused by different causes. In addition, the skin-care oil prepared by the application is used for clinically treating epigastric pain caused by drinking, can effectively exert the functions of astringing to stop bleeding, reducing swelling and promoting granulation, rapidly relieves the congestion and edema of gastric mucosa, and repairs the broken wound surface of gastric ulcer.
In order to achieve the first object, the present invention adopts the following technical measures:
the stomach-lavage skin-care oil for treating gastric ulcer is prepared from the following raw materials in parts by weight: 30-50 parts of astragalus membranaceus, 30-50 parts of angelica sinensis, 30-50 parts of garden burnet, 10-30 parts of bletilla striata, 10-30 parts of frankincense, 5-10 parts of radix scutellariae, 5-10 parts of coptis chinensis, 5-10 parts of rheum officinale, 5-10 parts of phellodendron amurense, 5-10 parts of rehmannia glutinosa, 5-10 parts of gynura procumbens, 10-15 parts of borneol and 1000-1500 parts of edible vegetable oil;
preferably, the stomach-lavage skin-care oil for treating gastric ulcer is prepared from the following raw materials in parts by weight: 50 parts of astragalus membranaceus, 50 parts of angelica sinensis, 50 parts of garden burnet, 30 parts of bletilla striata, 30 parts of frankincense, 10 parts of radix scutellariae, 10 parts of coptis chinensis, 10 parts of rheum officinale, 10 parts of cortex phellodendri, 10 parts of rehmannia glutinosa, 10 parts of gynura procumbens, 15 parts of borneol and 1000-1500 parts of edible vegetable oil;
preferably, the stomach-lavage skin-care oil for treating gastric ulcer is prepared from the following raw materials in parts by weight: 30 parts of astragalus membranaceus, 30 parts of angelica sinensis, 30 parts of garden burnet, 10 parts of bletilla striata, 10 parts of frankincense, 5 parts of scutellaria baicalensis, 5 parts of coptis chinensis, 5 parts of rheum officinale, 5 parts of phellodendron amurense, 5 parts of rehmannia glutinosa, 5 parts of gynura procumbens, 10 parts of borneol and 1000-1500 parts of edible vegetable oil;
The edible vegetable oil is selected from at least one of sesame oil, coconut oil, peanut oil, soybean oil, linseed oil, castor oil and olive oil, preferably from at least one of sesame oil, coconut oil and olive oil.
In order to achieve the second object, the present invention adopts the following technical measures:
a preparation method of the stomach-lavage skin-care oil for treating gastric ulcer comprises the following steps:
placing 50% -90% of the total edible vegetable oil into a container, adding dry powders of radix astragali, radix Angelicae sinensis, radix Sangusorbae, rhizoma Bletillae, radix Scutellariae, radix et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, and radix Gynostemmatis, and stirring; standing for soaking for 3-10 days, stirring at 55-65deg.C for 1-2 hr, stopping heating, adding Olibanum dry powder, filtering to remove residue, and collecting filtrate; when the temperature of the oil is reduced to 30-40 ℃, adding borneol and the rest edible vegetable oil into the mixture, fully stirring the mixture, and cooling the mixture to obtain the stomach-perfusing skin-growing oil for treating gastric ulcer.
Further, the edible vegetable oil is prepared from the following components in percentage by weight (2-4): 1 sesame oil and coconut oil, the steps of the preparation method are as follows:
placing sesame oil into a container, adding dry powders of radix astragali, radix Angelicae sinensis, radix Sangusorbae, rhizoma Bletillae, radix Scutellariae, radix et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, and radix Gynostemmatis, and stirring; standing for soaking for 3-10 days, stirring at 55-65deg.C for 1-2 hr, stopping heating, adding dry powder of milk, filtering to remove residue, and collecting filtered oil; when the oil temperature is reduced to 30-40 ℃, adding borneol and coconut oil into the mixture, fully stirring the mixture, and cooling the mixture to obtain the stomach-lavage skin-care oil for treating gastric ulcer.
Further, the steps of filtering and deslagging are as follows: shearing for 3-5 times at 20000rpm by flash extraction device; sieving with 5000 mesh sieve under negative pressure to remove residue.
Further, the dry powder of 11 Chinese medicinal materials such as astragalus root, angelica, garden burnet, bletilla tuber, baikal skullcap root, rhubarb, coptis root, amur corktree bark, rehmannia root, gynura procumbens, frankincense and the like is sieved by a 120-mesh sieve.
In order to achieve the third object of the present invention, the present invention also adopts the following technical measures:
the invention also provides application of the stomach-lavage skin-care oil in preparing a medicament for treating gastric ulcer caused by noxious stimulus.
Further, the gastric ulcer includes alcoholic acute gastric ulcer, non-steroidal anti-inflammatory drug chronic gastric ulcer and environmental cold-stimulated acute gastric ulcer.
The formula principle of each traditional Chinese medicine raw material of the invention is as follows:
astragalus root, angelica, garden burnet root, bletilla tuber, frankincense, borneol and the like are used for promoting blood circulation by removing blood stasis, reducing swelling and relieving pain, and are monarch drugs (drugs for activating qi-tonifying and promoting tissue regeneration, promoting blood circulation by removing blood stasis, so as to improve local microcirculation and enhance local damage resistance and repair capability); the baikal skullcap root, the coptis chinensis, the phellodendron bark, the rhubarb and the like are used as ministerial drugs (drugs for inhibiting gastric acid and killing helicobacter pylori are used for protecting ulcer surfaces from being damaged and preventing further deterioration); rehmannia root, gynura procumbens and the like astringe yin and promote tissue regeneration, remove putrefaction and treat sore, reduce swelling and discharge pus, and are used as auxiliary drugs (auxiliary drugs and ministerial drugs) to reconstruct the protective barrier of gastric mucosa; the vegetable oil (which is used for covering the ulcer surface by using the viscosity to prevent the wound surface from being further damaged) is used for harmonizing the medicines together to achieve the effects of detoxification and granulation promotion.
Compared with the prior art, the invention has the following advantages and effects:
research results show that the skin oil prepared by the invention can effectively play the roles of acid production, granulation promotion, anti-inflammatory and detumescence after being administrated by gastric lavage, obviously reduces inflammatory reaction of ulcer parts, achieves the effect of treating gastric ulcer, and has no obvious pathological influence on morphological mechanisms of various tissues and organs after long-time administration.
The skin oil has the following advantages for preventing and treating gastric ulcer: (1) the cost of the medicine is low, and no toxic or side effect is caused; (2) the medicine is directly applied to the ulcer part through gastric lavage, and the healing effect of the ulcer part is good; (3) has good curative effect on gastric ulcer caused by various factors (such as alcohol, non-steroidal anti-inflammatory drugs and environmental factors).
Drawings
FIG. 1 is a graph showing the effect of skin oil on treatment of alcoholic acute gastric ulcer (general view, gastric emptying rate analysis and tissue HE staining) in example 3.
As shown in FIG. 1, (1) the stomach generally looks like. Normal group mice have ordered gastric mucosa folds, the mucosa is light pink in color, and the whole stomach tissue is free from ulcers, congestion, edema and erosion; the gastric mucosa folds of the mice in the model group have no obvious outline, disordered arrangement, blurred edges, a great deal of congestion and redness and swelling of gastric tissues, a great deal of linear and sheet-shaped bleeding points, and the bleeding points with different sizes are visible in the gastric tissues. The gastric mucosa of the mice of Sanjiuweitai group is engorged with edema, and a large number of bleeding spots are linear; the gastric mucosa of the mice of the western medicine four-combined therapy group is light pink, the gastric mucosa is slightly edematous, and partial linear bleeding points are formed; the gastric mucosa of the mice of the skin-care oil group is pink, the mucosa edema almost disappears, no large-scale linear bleeding point is seen, the bleeding area is obviously reduced, and the bleeding position has a healing trend; (2) gastric ulcer gastric emptying rate analysis results. The gastric emptying rate of the mice in the model group was significantly increased relative to the blank group. Compared with the traditional Chinese medicine Sanjiuweitai group and western medicine tetrad therapy group, the gastric emptying rate of the skin oil group mice is obviously lower. (3) pathological observations of gastric ulcers. The gastric mucosa epithelium of the mice in the blank group has no obvious defect, the continuity is good, the glands are orderly arranged, the tissue structure of the mucosa tissue is clear in layer, and inflammatory cell infiltration is avoided; the gastric mucosa injury of the mice in the model group accumulates and the mucosa basal layer, and part of mucosa epithelial cells are damaged and shed, capillary blood vessel expands and is hyperemia, gland swelling, structural damage, inflammatory cell infiltration is obvious and reaches the muscular layer deeply, and the histopathological score is obviously higher than that of the mice in the blank group; the gastric mucosa of mice in the Sanjiuweitai group and the western medicine four-combined therapy group still lacks, the structural damage is obvious, a large amount of inflammatory cell infiltration is visible, and the histopathological score of the mice is improved relative to that of a model group.
FIG. 2 is a graph showing the effect of skin oil on treating non-steroidal anti-inflammatory drug gastric ulcers in mice (a general view, a graph of gastric emptying rate analysis, and a graph of tissue HE staining) in example 4.
As shown in FIG. 2, (1) the stomach generally looks like. Normal group mice have ordered gastric mucosa folds, the mucosa is light pink in color, and the whole stomach tissue is free from ulcers, congestion, edema and erosion; the gastric mucosa folds of the mice in the model group have no obvious outline, disordered arrangement and blurred edges, and are thinner than those of the normal group, the tissues have congestion and edema, and white spots with different sizes can be seen in the stomach tissues. Compared with the model group, the gastric mucosa of the mice in the traditional Chinese medicine small-sized and middle-sized group is still edematous and accompanied with white ulcer spots with different degrees; the gastric mucosa of the mice in the western medicine four-combined therapy group is visible in light pink, the degree of congestion edema is reduced, and white ulcer spots with different degrees are still visible; the congestion and edema of the gastric mucosa of the mice in the skin-care oil group almost disappear, the folds of the mucosa are approximately contoured, and no gastric ulcer spots with different degrees are found; (2) gastric ulcer gastric emptying rate analysis results. The gastric emptying rate of the mice in the model group was significantly increased relative to the blank group. Compared with the traditional Chinese medicine small-size Chinese medicine group and western medicine four-combined therapy group, the gastric emptying rate of the skin oil group mice is obviously lower and is closer to that of a blank group. (3) pathological observations of gastric ulcers. The gastric mucosa epithelium of the mice in the blank group has no obvious defect, good continuity, orderly gland arrangement, clear tissue structure layer of the mucosa and no inflammatory cell infiltration; the whole gastric mucosa of the model group mice is thinned, the damage is accumulated, the mucous membrane basal layer is severely reduced, the mucous membrane epithelial cells are thinned, the holes appear on part of wall cells, the main cells are reduced, the gastric fovea structure is clear, inflammation infiltration of neutrophils, lymphocytes and the like can be seen in the mucous membrane layer, the gastric gland tube arrangement disorder and reduction can be partially found, the serosa capillary dilation congestion is obviously higher than that of the blank group, and the histopathological score is obviously higher than that of the blank group; the gastric mucosa layer of mice in the traditional Chinese medicine small-size Chinese medicine group and western medicine four-combined therapy group is still thinned, parietal cells and main cells are still abnormal edema, the structure is still obviously destroyed, a large amount of inflammatory cell infiltration and vasodilation are still visible from the mucosa layer to the serosa layer, but the histopathological score of the mice is improved less than that of the model group; the mice with skin-growing oil groups have normal gastric mucosa morphological structure, the defect of the mucosa layer is light, normal epithelial cells, parietal cells and main cells are relatively normal, the infiltration of the mucosa layer to serosa inflammatory cells is less, the edema of cells is reduced, the vasodilation is reduced, and the pathology score is obviously improved relative to the model group.
FIG. 3 is a graph showing the effect of skin oil treatment on environmental cold-stimulated acute gastric ulcers in mice in example 5 (general view, gastric emptying rate analysis and tissue HE staining).
As shown in FIG. 3, (1) the stomach generally looks like. Normal group mice have ordered gastric mucosa folds, the mucosa is light pink in color, and the whole stomach tissue is free from ulcers, congestion, edema and erosion; the gastric mucosa folds of the mice in the model group are blurred in edge, punctate bleeding with different degrees can be seen among folds, the mucosa edema is serious, the color is dim, the mice are in a pale, colorless and blood-free state, the positions of the bleeding points are different, and the positions of the gastric ulcers are in dark red to yellow. Compared with the model group, the traditional Chinese medicine good adhesion pill group mice have no pale gastric mucosa color, still have mucosa edema and reduce bleeding parts; the gastric mucosa of the mice in the western medicine four-combined therapy group is still pale, the bleeding area is partially reduced, and the edema phenomenon of the mucosa is visible; the gastric mucosa of the mice of the skin-care oil group is pink, the edema of the mucosa almost disappears, the edge of the folds of the gastric mucosa is clearly visible, the bleeding area is obviously reduced, and the bleeding position is visible with healing marks; (2) gastric ulcer gastric emptying rate analysis results. The gastric emptying rate of mice in the model group was significantly increased. Compared with the traditional Chinese medicine Liangfu pill group and western medicine four-in-one therapy group, the gastric emptying rate of the skin oil group mice is relatively lower and is closer to that of the blank group. (3) pathological observations of gastric ulcers. The gastric mucosa epithelium of the mice in the blank group has no obvious defect, the continuity is good, the glands are orderly arranged, the tissue structure of the mucosa tissue is clear in layer, and inflammatory cell infiltration is avoided; the gastric mucosa epithelial layer of the mice in the model group drops, glands are arranged in disorder, a large number of red blood cells and inflammatory cells are gathered and reach the mucosal myolayer deeply, normal cells are eroded, a large number of red staining is locally carried out on the normal cells, a large number of yellow or brown necrotic tissues are visible on the epithelial layer, serous edema is serious, the structure is abnormal, and the histopathological score of the model group is obviously higher than that of a blank group; the gastric mucosa epithelial layer of the mice in the Chinese medicine Liangfu pill group and the western medicine four-in-one therapy group still can see necrotic tissues, a large amount of inflammatory cells infiltrate, serosal edema is obviously resolved, and the histopathological score is improved relative to that of the model group; the morphological structure of gastric mucosa surrounding gastric ulcer of mice in the skin-growing oil group tends to be normal, inflammatory cell infiltration is obviously reduced, only visible in a mucosal layer, the falling cells of a mucosal epithelial layer are obviously reduced, serosal layer edema is obviously improved, a damaged part is a new granulation tissue, and the pathological score is obviously improved.
FIG. 4 is a photograph showing the structure of tissues such as liver, kidney, small intestine, etc. of a mouse after a long-term and large-amount of the gastric lavage skin tonic oil in example 6 (HE staining chart).
As shown in fig. 4, after 15 consecutive days of gastric lavage administration of the skin oil (skin oil prepared in example 1), intestinal villi of the small intestine tissue of the mice are arranged in order, and the mucosal layer, the muscular layer and the serosa tissue structure are complete; the liver lobule in liver tissue has normal structure, regular hepatic chordae distribution and no fat phenomenon in the tissue; kidney glomeruli form normal and kidney medullary cells are ordered in kidney tissue.
Detailed Description
The following applicant will make further details of the technical scheme and application of the present invention with reference to specific examples. It should be understood that the following should not be taken in any way as limiting the scope of the invention.
The applicant has carried out a series of scientific experiments and verification on the effect of skin oil on treating gastric ulcer, confirms that the compound can effectively treat and control mucosal congestion and edema of gastric ulcer parts, reduce bleeding area, reduce gastric emptying rate, eliminate inflammatory reaction, quickly repair gastric ulcer wound surface and protect the morphological structure of gastric tissues. Meanwhile, toxicity evaluation experiments of a large amount of skin-growing oil for stomach irrigation for a long time show that the skin-growing oil prepared by the invention has no obvious damage influence on organs such as liver, kidney, small intestine and the like of a normal mouse.
The 11 traditional Chinese medicinal materials used in the following examples, such as radix astragali, radix Angelicae sinensis, radix Sangusorbae, rhizoma Bletillae, radix Scutellariae, radix et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, gynura procumbens and Olibanum, are all sieved by 120 mesh sieve.
Example 1: a preparation method of skin-care oil comprises the following steps:
placing 1000g of sesame oil into a container, then adding 50g of dry powder of astragalus, angelica and sanguisorba respectively, 30g of dry powder of bletilla striata, 10g of dry powder of scutellaria baicalensis, rheum officinale, coptis chinensis, phellodendron amurense, rehmannia glutinosa and gynura procumbens respectively, and uniformly stirring; after standing and soaking for 10 days, stirring and heating are carried out for 2 hours at the oil temperature of 55 ℃. After stopping heating, 30g of dry powder of the cream is added, and then sheared by a flash extraction device at 20000rpm for 5 times (5 min each time); sieving with 5000 mesh sieve under negative pressure, and collecting filtered oil; when the oil temperature is reduced to 40 ℃, 15g of borneol and 500g of coconut oil are added into the mixture, the mixture is fully stirred uniformly, cooled to room temperature, bottled and stored in a closed manner.
Example 2: a preparation method of skin-care oil comprises the following steps:
placing 800g of sesame oil into a container, then adding 30g of dry powder of astragalus, angelica and sanguisorba respectively, 10g of dry powder of bletilla striata, 5g of dry powder of scutellaria baicalensis, rheum officinale, coptis chinensis, phellodendron amurense, rehmannia and gynura procumbens respectively, and uniformly stirring; after 3 days of standing and soaking, stirring and heating are carried out for 1 hour at the oil temperature of 65 ℃. After stopping heating, 10g of dry powder of the cream is added, and then sheared by a flash extraction device at 20000rpm for 3 times (5 min each time); sieving with 5000 mesh sieve under negative pressure, and collecting filtered oil; when the oil temperature is reduced to 30 ℃, 10g of borneol and 200g of coconut oil are added into the mixture, the mixture is fully stirred uniformly, cooled to room temperature, bottled and stored in a closed manner.
Example 3 effect of the skin oil prepared in example 1 on treatment of acute gastric ulcer in alcoholic mice
The test animals were SPF-grade Kunming mice (18-22 g) 25 (supplied by the Hubei province center for disease prevention control). The free drinking water diet is adopted, the room temperature of the feeding room is kept at 25+/-1 ℃, and the light and dark period is 12 hours. 1. Preparation and administration of acute gastric ulcer model of alcoholic mice
Mice were equally divided into 5 groups according to the body weight randomization block method: normal (Control), model (Model), skin oil (SFO), sanjiuweitai (chinese medicine) and rabeprazole combined lizhuwei triad (tetrad therapy, quadruple Therapy, western medicine); each group of 5. After 7 days of adaptive feeding, each group was subjected to gastric lavage for 7 days, normal and model groups each had a normal saline of 0.1mL/10g each day, a skin oil group had a normal saline of 0.1mL/10g each day, a Sanjiuweitai group had a suspension of 1.154g/mL Sanjiuweitai particles (Sanjiuweitai particles, sanjiuzhu medical Co., ltd.) dissolved in ultrapure water each day, a rabeprazole-Lizhuwei triple group had a normal saline of 0.37mg/mL rabeprazole (rabeprazole sodium enteric capsule, lizhu group Lizhu pharmaceutical factory) and a suspension of 40mg/mL Lizhu-Lizhu triple (bismuth citrate tablet/tinidazole tablet/clarithromycin tablet composite package), each group had a normal saline of 0.1mL/10g each day.
On day 7 of the gastric lavage cycle, mice were fasted for 24 hours and water-stopped for 4 hours, and all model mice were given 0.1ml/10g of absolute ethanol for gastric lavage, and after 3 minutes of success of gastric lavage, the mice developed symptoms such as soft whole body, mental stress, acceleration of respiratory heartbeat, etc. The mice were fasted and kept water-free during 4 hours after gastric lavage, and the remaining feeding conditions were the same.
2. General observation of gastric ulcer part of mice, gastric emptying rate detection and pathological staining
4 hours after administration of the modeling agent (absolute ethyl alcohol), the mice are sacrificed, after the whole stomach of the mice is taken, the blood trace on the stomach surface is removed, the 1 st weighing (the whole stomach weight) is performed, the appetizing tissue is sheared along the greater curvature of the stomach, the appetizing tissue is rinsed with 0.9% sodium chloride solution, the water is sucked by filter paper, and the 2 nd weighing (the net stomach weight) is performed; the calculation formula is as follows: gastric emptying rate (%) = (total stomach weight-net stomach weight)/total stomach weight×100%. Gastric mucosal ulcers were visually observed and recorded by photographing, and the length and width of the ulcer stripes were measured using vernier calipers. Gastric ulcers were also scored on mouse gastric tissue using the gastric ulcers as shown in table 1. The stomach tissue of the mice was then fixed with 10% formalin at 10 times the sample volume, dehydrated and embedded, serial sections 4 μm thick, HE stained and observed under a microscope for changes in tissue structure, and then pathologically scored using gastric ulcer pathology scoring as in table 2.
3. Experimental results
1) General observations of alcoholic gastric ulcers
As shown in FIG. 1A, FIG. 1B and FIG. 1C, gastric mucosa folds of mice in normal group are orderly arranged, the mucosa is light pink, and the whole gastric tissue is free from ulcers, congestion, edema and erosion (gastric ulcer score is 0+ -0; gastric ulcer area is 0.04+ -0.02 mm) 2 ) The method comprises the steps of carrying out a first treatment on the surface of the The gastric mucosa folds of the mice in the model group have no obvious outline, disordered arrangement, blurred edges, a large amount of congestion and reddening of gastric tissues, a large amount of linear and sheet bleeding points, and the bleeding points with different sizes are visible in the gastric tissues, which indicates that the existing gastric ulcer bleeding occurs (the gastric ulcer score is 4.20+/-0.37, and the gastric ulcer area is 32.28+/-7.29 mm) 2 ) The above results indicate that the molding using absolute ethanol was successful. Compared with the model group, the traditional Chinese medicine Sanjiuweitai group mice can be seen, the gastric mucosa is still congested and dropsy, and a large number of linear bleeding points (gastric ulcer score is 3.40+/-0.60, p)>0.05; the gastric ulcer area is 26.20 +/-4.41 mm 2 ，p>0.05 A) is provided; the gastric mucosa of mice in western medicine four-therapy group can be seen as light pink, gastric mucosa edema is improved, and partial linear bleeding points (gastric ulcer score is 2.60+/-0.50, p)<0.05; the gastric ulcer area is 18.87+ -4.26 mm 2 ，p>0.05 A) is provided; the gastric mucosa of mice in the skin oil group can be seen to be nearly pink with that of the mice in the normal group, the mucosa edema almost disappears, no large-scale linear bleeding point is seen, the bleeding area is obviously reduced, and the bleeding point has a healing trend (gastric ulcer score is 2.40+/-0.40, p) <0.01；The gastric ulcer area is 10.21+/-4.25 mm 2 ，p<0.01). The traditional Chinese medicine Sanjiuweitai has poor treatment effect on the alcoholic mouse gastric ulcer, the western medicine tetrad therapy medicine has a certain treatment effect on the alcoholic mouse gastric ulcer, the skin oil has obvious treatment effect on the alcoholic mouse gastric ulcer, and the stomach hemorrhage caused by alcohol can be treated while the gastric mucosa congestion and edema of the skin oil are improved.
2) Gastric emptying rate analysis of alcoholic gastric ulcers
As shown in fig. 1D, the gastric emptying rate (0.63±0.02) of the mice in the model group was significantly increased relative to that of the mice in the blank group (0.37±0.06), which indicates that the mice with alcoholic gastric ulcer had abnormal gastric motility, the contents in the stomach were not normally discharged, and the gastric pressure was too high after the gastric ulcer had occurred. Whereas the gastric emptying rate (0.45+ -0.02, p < 0.05) of the skin oil group is closer to that of the blank group than the traditional Chinese medicine Sanjiuweitai group (0.57+ -0.04, p > 0.05) and the western medicine tetrad therapy group (0.50+ -0.05, p > 0.05), so that the skin oil can relieve gastric motility abnormality, normally discharge stomach contents and reduce stomach pressure after alcoholic gastric ulcer occurs.
3) Pathological observation of alcoholic gastric ulcer
As shown in fig. 1E and 1F, the gastric mucosal epithelium of the mice in the blank group has no obvious defect, good continuity, orderly glandular arrangement, clear tissue structure layer of the mucosa and no inflammatory cell infiltration; the gastric mucosa injury accumulation and the mucosa basal layer of the mice in the model group can be seen as the damaged and shed part of mucosa epithelial cells, telangiectasia congestion, gland swelling, structural damage, obvious inflammatory cell infiltration and deep muscular layer, and the histopathological score (9.20+/-0.37) is obviously higher than that of the blank group (0+/-0); the gastric mucosa of mice in the traditional Chinese medicine Sanjiuweitai group and the western medicine tetrad therapy group still is deficient, the structural damage is obvious, a large amount of inflammatory cell infiltration is visible, and the histopathological scores of the Sanjiuweitai group (7.20+/-0.37, p < 0.05) and the tetrad therapy group (5.20+/-0.37, p < 0.01) are improved relative to the model group (9.20+/-0.37); the morphological structure of gastric mucosa around gastric ulcer of mice in the skin-care oil group tends to be normal, the mucosa defect of the ulcer surface is light, the damaged part is provided with a new granulation tissue, inflammatory cell infiltration is less, and the pathological score (2.80+/-0.37; p < 0.001) is obviously improved compared with the model group.
EXAMPLE 4 therapeutic Effect of the skin oil prepared in example 2 on chronic gastric ulcers in non-steroidal anti-inflammatory drug mice
The test animals were SPF-grade Kunming mice (18-22 g) 25 (supplied by the Hubei province center for disease prevention control). The free drinking water diet is adopted, the room temperature of the feeding room is kept at 25+/-1 ℃, and the light and dark period is 12 hours. 1. Preparation and administration of non-steroidal anti-inflammatory drug type chronic gastric ulcer model of mice
Mice were equally divided into 5 groups according to the body weight randomization block method: normal group (Control), model group (Model), skin oil group (SFO), small building group (traditional Chinese medicine group), rabeprazole and lizhuwei triple group (four-combined therapy group, quadruple Therapy, western medicine group); each group of 5. After 7 days of adaptive feeding, mice were continuously gavaged for 10 days, both the normal and model groups were gavaged with 0.1mL/10g of physiological saline per day, the skin oil group was gavaged with 0.1mL/10g of skin oil per day, the small-build-in group was gavaged with 0.585g/mL of suspension of small-build-in particles (small-build-in particles, hunan Kang Erjia pharmaceutical Co., ltd.) dissolved in ultrapure water per day, the rabeprazole (rabeprazole sodium enteric capsule, lizhu group Lizhu pharmaceutical factory) and the 40mg/mL of suspension of Lizhu (bismuth citrate potassium tablet/tinidazole tablet/clarithromycin tablet composite package, lizhu group Lizhu pharmaceutical factory) were gavaged with 0.1mL/10g per day, each group was gavaged with 1 time per day. After day 5 of gavage, mice were additionally gavaged with 0.1mL/10g of 20mg/mL aspirin suspension in ultrapure water 2 hours after gavage for 5 days in succession.
2. General observation of gastric ulcer part of mice, gastric emptying rate detection and pathological staining
After 10 days of continuous gastric lavage, the mice are sacrificed, after the whole stomach of the mice is taken, the blood trace on the surface of the stomach is removed, the 1 st weighing (the whole stomach weight) is performed, appetizing tissues are sheared along the greater curvature of the stomach, the appetizing tissues are rinsed with 0.9% sodium chloride solution, the water is sucked by filter paper, and the 2 nd weighing (the net stomach weight) is performed; the calculation formula is as follows: gastric emptying rate (%) = (total stomach weight-net stomach weight)/total stomach weight×100%. Characterization of gastric mucosal layer ulcers was visually observed and recorded by photographing, and length and width of ulcer stripes were measured using vernier calipers. Gastric ulcers were also scored on mouse gastric tissue using the gastric ulcers as shown in table 1. The stomach tissue of the mice was then fixed with 10% formalin at 10 times the sample volume, dehydrated and embedded, serial sections 4 μm thick, HE stained and observed under a microscope for changes in tissue structure, and then pathologically scored using gastric ulcer pathology scoring as in table 2.
3. Experimental results
1) General observations of non-steroidal anti-inflammatory drug-induced gastric ulcers
As shown in FIG. 2A, FIG. 2B and FIG. 2C, gastric mucosa folds of mice in normal group are orderly arranged, the mucosa is light pink, and the whole stomach tissue is free from ulcers, congestion, edema and erosion (gastric ulcer score is 0+ -0; gastric ulcer area is 0.20+ -0.02 mm) 2 ) The method comprises the steps of carrying out a first treatment on the surface of the The model group mice have no obvious outline, disordered arrangement and blurred edges of gastric mucosa folds, and have thinner gastric wall and congestion and edema tissues than the normal group mice, and white spots with different sizes and wide range are visible in the gastric tissues, which indicates that the existing ulcers appear (gastric ulcer score is 2.80+/-0.37; gastric ulcer area is 20.32+/-1.98 mm) 2 ). The above results indicate that modeling with non-steroidal anti-inflammatory drugs was successful. The mice in the traditional Chinese medicine small-medium group can be seen relative to the model group, and the gastric mucosa is still edema and is accompanied by white ulcer spots with different degrees (the gastric ulcer score is 2.20+/-0.20, p)>0.05; the gastric ulcer area is 15.26+/-1.04 mm 2 ，p>0.05 A) is provided; the gastric mucosa of mice in western medicine four-therapy group has reduced degree of pale pink, congestion and edema, and white ulcer spots with different degrees (gastric ulcer score of 1.60+ -0.24, p)<0.05; the gastric ulcer area is 13.36+ -2.28 mm 2 ，p>0.05 A) is provided; the congestion and edema of the gastric mucosa of mice in the skin oil group almost disappeared, the mucosa folds were seen to be roughly contoured, and no gastric ulcer spots (gastric ulcer score of 1.40.+ -. 0.40, p) were found to various degrees<0.05; the gastric ulcer area is 2.48 plus or minus 0.81mm 2 ，p<0.001). The result shows that the traditional Chinese medicine Xiaojian Chinese and western medicine tetrad therapy has common treatment effect on the chronic gastric ulcer of mice, can not improve the congestion and edema of gastric mucosa and the healing of ulcer surface of the gastric ulcer, and the skin oil can treat the non-steroidal anti-inflammatory drug gastric ulcer of mice The ulcer has remarkable treatment effect, and can treat gastric tissue large-area ulcer caused by nonsteroidal anti-inflammatory drugs while improving the congestion and edema of gastric mucosa.
2) Analysis of gastric emptying rate of non-steroidal anti-inflammatory drug gastric ulcers
As shown in fig. 2D, the gastric emptying rate (0.58±0.04) of the mice in the model group was significantly increased relative to that of the mice in the blank group (0.42±0.07), which indicates that gastric motility abnormality, abnormal discharge of gastric contents and gastric overpressure exist after gastric ulcer of the mice with non-steroidal anti-inflammatory drugs. The gastric emptying rate (0.44+/-0.05, p < 0.05) of the skin oil group mice is closer to that of the blank group for the traditional Chinese medicine small-size middle-size group (0.47+/-0.08, p > 0.05) and the western medicine four-combined therapy group (0.45+/-0.05, p > 0.05), so that the skin oil can relieve abnormal gastric motility, normally discharge stomach contents and reduce stomach pressure after the non-steroidal anti-inflammatory drug gastric ulcer occurs.
3) Pathological observation of non-steroidal anti-inflammatory drug gastric ulcer
As shown in fig. 2E and 2F, the gastric mucosal epithelium of the mice in the blank group has no obvious defect, good continuity, orderly glandular arrangement, clear tissue structure layer of the mucosa and no inflammatory cell infiltration; the whole gastric mucosa of the mice in the model group is thinned, the damage is accumulated and the mucosa basal layer is severely reduced, the mucosa epithelial cells are thinned, the hollow appears on part of wall cells, the main cells are reduced, the gastric fovea structure is clear, the inflammation infiltration of neutrophils, lymphocytes and the like can be seen in the mucosa basal layer, the gastric gland tube arrangement disorder and reduction can be partially found, the serosa capillary expansion congestion is caused, and the histopathological score (7.60+/-0.50) is obviously higher than that of the blank group (0+/-0); the gastric mucosa layer of mice in the traditional Chinese medicine small-size Chinese medicine group and western medicine four-combined therapy group is still thinned, parietal cells and main cells are still abnormal edema, the structure is still obviously destroyed, a large amount of inflammatory cell infiltration and vasodilation are still visible from the mucosa layer to the serosa layer, and the histopathological score of the small-size Chinese medicine group (6.60+/-0.40, p > 0.05) and the four-combined therapy group (6.00+/-0.31, p < 0.05) are improved slightly relative to the model group (7.60+/-0.50); the mice in the skin-growing oil group have normal gastric mucosa morphological structure, the defect of the mucosa layer is light, normal epithelial cells, parietal cells and main cells are relatively normal, inflammatory cells from the mucosa layer to the serosa layer are less in infiltration, cellular edema is reduced, vasodilation is reduced, and the pathological score (3.40+/-0.24; p < 0.01) is obviously improved relative to the model group.
Example 5 effect of the skin oil prepared in example 1 on treatment of acute gastric ulcer in environmentally cold-stimulated mice
Normal male Kunming mice (18-22 g) (supplied by the Hubei province disease prevention control center). The free drinking water diet is adopted, the room temperature of the feeding room is kept at 25+/-1 ℃, and the light and dark period is 12 hours.
1. Preparation and administration of environmental cold-stimulated mice acute gastric ulcer model
Mice were equally divided into 5 groups according to the body weight randomization block method: normal (Control), model (Model), skin oil (SFO), liangbu Pill (traditional Chinese medicine), rabeprazole and Lizhuwei triplet (tetrad therapy, quadruple Therapy, western medicine); each group of 6. After 7 days of adaptive feeding, each group was subjected to gastric lavage for 7 days, normal and model groups each had a normal saline of 0.1mL/10g each day, a skin oil group had a normal saline of 0.1mL/10g each day, a Lifu pill group had a suspension of 0.4g/mL Lifu pill (Lifu pill, beijing Tongsheng Co., ltd.) dissolved in ultrapure water each day, a rabeprazole-Liuzhuwei triad group had a gastric lavage of 0.37mg/mL in ultrapure water (rabeprazole sodium enteric capsule, lizhu group Lizhu pharmaceutical factory) and a suspension of 40mg/mL Lizhu (bismuth potassium citrate tablet/tinidazole tablet/clarithromycin tablet composite package, lizhu group Lizhu pharmaceutical factory) each had a gastric lavage of 0.1 time each day.
Mice were fasted for 24 hours and water was stopped for 4 hours 7 days after gastric lavage. After the mouse is put into a simple mouse cold restraint device (an improved EP pipe), the mouse is vertically erected in a water bath kettle with the water temperature stabilized at 20 ℃, a mouse vent hole is upward, and the xiphoid process part of the mouse is kept to be level on the horizontal plane. After the water immersion cold restraint stress lasts for 8 hours, the experiment is terminated, the mice are taken out from the cold restraint device and placed on an experiment table, the air passage of the mice is kept smooth in the process, and then the hair of the mice is dried.
2. General observation of gastric ulcer part of mice, gastric emptying rate detection and pathological staining
After the cold constraint experiment is finished, the mice are sacrificed, after the whole stomach of the mice is taken, the blood trace on the surface of the stomach is removed, the 1 st weighing (the whole stomach weight) is carried out, appetizing tissues are sheared along the greater curvature of the stomach, the appetizing tissues are rinsed by 0.9 percent sodium chloride solution, the water is sucked by filter paper, and the 2 nd weighing (the net stomach weight) is carried out; the calculation formula is as follows: gastric emptying rate (%) = (total stomach weight-net stomach weight)/total stomach weight×100%. Characterization of gastric mucosal layer ulcers was visually observed and recorded by photographing, and length and width of ulcer stripes were measured using vernier calipers. Gastric ulcers were also scored on mouse gastric tissue using the gastric ulcers as shown in table 1. The stomach tissue of the mice was then fixed with 10% formalin at 10 times the sample volume, dehydrated and embedded, serial sections 4 μm thick, HE stained and observed under a microscope for changes in tissue structure, and then pathologically scored using gastric ulcer pathology scoring as in table 2.
3. Experimental results
1) General observations of environmental Cold-stimulated gastric ulcers
As shown in FIG. 3A, FIG. 3B and FIG. 3C, gastric mucosa folds of mice in normal group are orderly arranged, the mucosa is light pink, and the whole stomach tissue is free from ulcers, congestion, edema and erosion (gastric ulcer score is 0+ -0; gastric ulcer area is 0.20+ -0.20 mm) 2 ) The method comprises the steps of carrying out a first treatment on the surface of the The model group mice have the characteristics that the folds of gastric mucosa are blurred in edge, punctiform bleeding with different degrees can be seen among folds, the mucous membrane edema is serious, the color is dim, the pale, colorless and blood-free state is realized, the positions of all bleeding points are different, the positions of gastric ulcers are in dark red to yellow (the gastric ulcer score is 4.00+/-0.31, and the gastric ulcer area is 4.86+/-1.13 mm) 2 ). The above results indicate that modeling was successful using ambient cold stimulus. Compared with the model group, the mice with the Chinese medicine good adhesion pill group have no pallor of gastric mucosa, still have mucosa edema, and have bleeding part reduced (gastric ulcer score is 2.80+ -0.37, p)<0.05; the gastric ulcer area is 1.66+ -0.31 mm 2 ，p<0.05 A) is provided; mice with western medicine four-combined therapy group still have pale gastric mucosa, bleeding area is partially reduced, and edema phenomenon (gastric ulcer score of 2.40+ -0.24, p) exists in the mucosa<0.01; the gastric ulcer area is 1.24+ -0.31 mm 2 ，p<0.01)The method comprises the steps of carrying out a first treatment on the surface of the The gastric mucosa of mice in the skin-care oil group can be seen to be nearly pink with that of mice in the normal group, but not pale and bloody in the model group, the mucosal edema almost disappears, the edge of gastric mucosa folds is clearly seen, the bleeding area is obviously reduced, and the bleeding position can be seen to have healing marks (gastric ulcer score is 2.00+/-0.31, p)<0.001; the gastric ulcer area is 0.38+/-0.04 mm 2 ，p<0.001). The traditional Chinese medicine good adhesion pill and western medicine four-combined therapy medicine have limited treatment effect on the environmental cold-stimulus gastric ulcer of mice, and the skin oil has obvious treatment effect on the environmental cold-stimulus gastric ulcer of the mice, and can treat gastric bleeding caused by the environment while improving pale gastric mucosa without blood.
2) Analysis of gastric emptying rate of environmental cold-stimulated gastric ulcers
As shown in fig. 3D, the gastric emptying rate (0.58±0.04) of the model group mice was significantly increased relative to the blank group (0.42±0.07). This indicates that the environmental cold-stimulated gastric ulcer mice have abnormal gastric motility, the contents in the stomach cannot be normally discharged, and the stomach pressure is too high after gastric ulcer occurs. Whereas the rate of gastric emptying (0.44.+ -. 0.05; p < 0.05) of the skin oil group is closer to that of the blank group than that of the traditional Chinese medicine Liangfu pill group (0.47.+ -. 0.08; p > 0.05) and western medicine four-way therapy group (0.45.+ -. 0.05; p > 0.05), so that the skin oil can relieve abnormal gastric motility, normally discharge gastric contents and reduce gastric pressure after the occurrence of environmental cold-stimulated gastric ulcer.
3) Pathological observation of environmental cold-stimulated gastric ulcer
As shown in fig. 3E and 3F, the gastric mucosal epithelium of the mice in the blank group has no obvious defect, good continuity, orderly glandular arrangement, clear tissue structure layer of the mucosa and no inflammatory cell infiltration; the gastric mucosa epithelial layer of the mice in the model group is shed, glands are arranged in disorder, a large number of red blood cells and inflammatory cells are gathered and reach the mucosal myolayer deeply, normal cells are eroded, a large number of red staining is locally carried out on the normal cells, a large number of yellow or brown necrotic tissues are visible on the epithelial layer, serous edema is serious, the structure is abnormal, and the histopathological score (8.00+/-0.44) is obviously higher than that of the blank group (0+/-0); the gastric mucosa epithelial layer of the mice in the traditional Chinese medicine good-adhesion pill group and the western medicine four-combined therapy group still can see necrotic tissues, a large amount of inflammatory cells infiltrate, serosal edema is obviously resolved, and the histopathological scores of the good-adhesion pill group (6.40+/-0.50; p < 0.05) and the four-combined therapy group (5.40+/-0.50; p < 0.01) are improved relative to the model group (8.00+/-0.44); the morphological structure of gastric mucosa surrounding gastric ulcer of mice in the skin-growing oil group tends to be normal, inflammatory cell infiltration is obviously reduced, only visible in a mucosal layer, the falling cells of a mucosal epithelial layer are obviously reduced, serosal edema is obviously improved, a damaged part is a new granulation tissue, and the pathological score (3.60+/-0.40; p < 0.001) is obviously improved relative to a model group.
TABLE 1
TABLE 2
Example 6 influence of a long-term, high-volume, peel-oil lavage on liver, kidney, and Small intestine tissue Structure of healthy mice 1 measurement of liver, kidney, and Small intestine tissue Structure index of healthy mice after Peel-oil lavage
10 male mice (weight: 18-20 g) were obtained from six-week-old experiment, and were equally divided into a skin oil group (skin oil prepared in example 1) and a blank group (physiological saline of equal amount); each group of 5. After 15 days of continuous gastric lavage administration of skin oil (0.5 mL/20g body weight; 1 time per day), the mice of each group were sacrificed under anesthesia and tissues of liver, kidney, small intestine were HE stained and structural evaluation was performed.
2. Experimental results
As shown in fig. 4, after 15 consecutive days of gastric lavage administration of the skin oil to the mice, intestinal villi of small intestine tissues of the mice are orderly arranged, and the structures of mucosal layers, muscular layers and serous tissues are complete; the liver lobule in liver tissue has normal structure, regular hepatic chordae distribution and no fat phenomenon in the tissue; kidney glomeruli form normal and kidney medullary cells are ordered in kidney tissue. In other words, according to pathological evaluation of tissue structure, compared with the normal group, after the skin oil is administrated by lavage, the tissue structure of each organ is not abnormal, whether it is liver or kidney and small intestine of the mice.
Claims (10)
1. The stomach-lavage skin-care oil for treating gastric ulcer is characterized by being prepared from the following raw materials in parts by weight:
30-50 parts of astragalus membranaceus, 30-50 parts of angelica sinensis, 30-50 parts of garden burnet, 10-30 parts of bletilla striata, 10-30 parts of frankincense, 5-10 parts of radix scutellariae, 5-10 parts of coptis chinensis, 5-10 parts of rheum officinale, 5-10 parts of cortex phellodendri, 5-10 parts of rehmannia glutinosa, 5-10 parts of gynura procumbens, 10-15 parts of borneol and 1000-1500 parts of edible vegetable oil.
2. The stomach-lavage skin-care oil for treating gastric ulcer according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:
50 parts of astragalus membranaceus, 50 parts of angelica sinensis, 50 parts of garden burnet, 30 parts of bletilla striata, 30 parts of frankincense, 10 parts of radix scutellariae, 10 parts of coptis chinensis, 10 parts of rheum officinale, 10 parts of cortex phellodendri, 10 parts of rehmannia glutinosa, 10 parts of gynura procumbens, 15 parts of borneol and 1000-1500 parts of edible vegetable oil; or (b)
The material is prepared from the following raw materials in parts by weight: 30 parts of astragalus, 30 parts of angelica, 30 parts of garden burnet, 10 parts of bletilla striata, 10 parts of frankincense, 5 parts of baikal skullcap root, 5 parts of coptis root, 5 parts of rheum officinale, 5 parts of amur corktree bark, 5 parts of rehmannia root, 5 parts of gynura procumbens, 10 parts of borneol and 1000-1500 parts of edible vegetable oil.
3. The stomach-invigorating skin oil for treating gastric ulcer according to claim 1 or 2, wherein the edible vegetable oil is at least one selected from sesame oil, coconut oil, peanut oil, soybean oil, linseed oil, castor oil and olive oil.
4. A method for preparing the stomach-lavage skin-care oil for treating gastric ulcer according to any one of claims 1 to 3, which comprises the following steps:
placing 50% -90% of the total edible vegetable oil into a container, adding dry powders of radix astragali, radix Angelicae sinensis, radix Sangusorbae, rhizoma Bletillae, radix Scutellariae, radix et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, and radix Gynostemmatis, and stirring; standing for soaking for 3-10 days, stirring at 55-65deg.C for 1-2 hr, stopping heating, adding dry powder of milk, filtering to remove residue, and collecting filtered oil; when the temperature of the oil is reduced to 30-40 ℃, adding borneol and the rest edible vegetable oil into the mixture, fully stirring the mixture, and cooling the mixture to obtain the stomach-perfusing skin-growing oil for treating gastric ulcer.
5. The method for preparing the gastric lavage skin generating oil for treating gastric ulcer according to claim 4, wherein the edible vegetable oil is prepared from (2-4): 1 sesame oil and coconut oil, the steps of which are as follows:
Placing sesame oil into a container, adding dry powders of radix astragali, radix Angelicae sinensis, radix Sangusorbae, rhizoma Bletillae, radix Scutellariae, radix et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, and radix Gynostemmatis, and stirring; standing for soaking for 3-10 days, stirring at 55-65deg.C for 1-2 hr, stopping heating, adding dry powder of milk, filtering to remove residue, and collecting filtered oil; when the oil temperature is reduced to 30-40 ℃, adding borneol and coconut oil into the mixture, fully stirring the mixture, and cooling the mixture to obtain the stomach-lavage skin-care oil for treating gastric ulcer.
6. The method for preparing the stomach-lavage skin generating oil for treating gastric ulcer according to claim 4 or 5, wherein the step of filtering to remove the residues is: after 3-5 times of high-speed shearing at 20000rpm by a flash extraction device, the residue is removed by a 5000-mesh sieve under negative pressure.
7. The method for preparing gastric lavage skin regeneration oil for treating gastric ulcer according to claim 4 or 5, wherein the dry powders of radix astragali, radix Angelicae sinensis, radix Sanguisorbae, rhizoma Bletillae, radix Scutellariae, radix Et rhizoma Rhei, rhizoma Coptidis, cortex Phellodendri, radix rehmanniae, radix Gynostemmatis, and Olibanum are all 120 mesh sieves.
8. Use of a gavage skin care oil according to any one of claims 1 to 3 or obtained by a method according to any one of claims 4 to 7 in the manufacture of a medicament for the treatment of gastric ulcers.
9. Use of a lavage skin care oil according to any one of claims 1 to 3 or a lavage skin care oil obtained according to any one of claims 4 to 7 for the preparation of a medicament for the treatment of gastric ulcers caused by noxious stimuli.
10. The use according to claim 8 or 9, wherein the gastric ulcer comprises an alcoholic acute gastric ulcer, a non-steroidal anti-inflammatory drug chronic gastric ulcer and/or an environmental cold-stimulated acute gastric ulcer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310849834.9A CN116920049B (en) | 2023-07-12 | 2023-07-12 | Skin-care oil for treating gastric ulcer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310849834.9A CN116920049B (en) | 2023-07-12 | 2023-07-12 | Skin-care oil for treating gastric ulcer and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116920049A true CN116920049A (en) | 2023-10-24 |
| CN116920049B CN116920049B (en) | 2024-05-31 |
Family
ID=88388887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310849834.9A Active CN116920049B (en) | 2023-07-12 | 2023-07-12 | Skin-care oil for treating gastric ulcer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116920049B (en) |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464620A (en) * | 1994-07-01 | 1995-11-07 | Zhao; Xinxian | Pharmaceutical composition for treating gastrointestinal disease |
| KR970020114A (en) * | 1995-10-26 | 1997-05-28 | 안봉환 | Anti-ulcer agent containing glutinous rice extract and beverage for preventing ulcer |
| CN102895526A (en) * | 2012-10-31 | 2013-01-30 | 唐和斌 | Externally-applied skin-generating oil for treatment of burn and preparation method and application thereof |
| CN103446488A (en) * | 2012-05-29 | 2013-12-18 | 黄勤 | Drug for protecting gastric mucosa |
| CN103906526A (en) * | 2011-10-25 | 2014-07-02 | 株式会社爱茉莉太平洋 | Wrap fermentation method using medicinal flower, and composition for external application onto the skin using same |
| CN105012702A (en) * | 2015-08-19 | 2015-11-04 | 唐和斌 | Application of externally used skin generation oil in preparation of drugs for preventing or treating diabetic peripheral circulation disturbance and foot ulcer |
| CN105343806A (en) * | 2015-12-17 | 2016-02-24 | 都炳霞 | Traditional Chinese medicine preparation for treating gastritis and gastric ulcer |
| CN106075071A (en) * | 2016-07-27 | 2016-11-09 | 张志杰 | A kind of Chinese medicine composition treating gastric ulcer and duodenal ulcer |
| CN109078116A (en) * | 2018-10-30 | 2018-12-25 | 黄中杰 | It is a kind of for treating the pure Chinese medicine Sucralfate and preparation method of gastric ulcer |
| CN109939182A (en) * | 2019-04-03 | 2019-06-28 | 中南民族大学 | A kind of skin-generating oil and its preparation method and application for treating ulcerative colitis |
| CN109939183A (en) * | 2019-04-03 | 2019-06-28 | 中南民族大学 | A kind of oral skin-generating oil and its preparation method and application for treating oral cavity burn and scald |
| DE102017131443A1 (en) * | 2017-12-29 | 2019-07-04 | Mingqiu Li | Chinese medicine for the treatment of gastric ulcers |
| CN111298053A (en) * | 2018-11-25 | 2020-06-19 | 佳木斯烧伤专科医院 | Bezoar dragon bone ointment for treating hemorrhoid |
| KR20200099777A (en) * | 2019-02-15 | 2020-08-25 | 상하이 지슈아이 바이오 테크놀로지 컴퍼니 리미티드 | Chinese medicine for gastric ulcer treatment |
| CN112891437A (en) * | 2021-04-22 | 2021-06-04 | 湘西自然生物科技有限公司 | Traditional Chinese medicine composition for treating gastric ulcer and preparation method thereof |
| CN113599458A (en) * | 2021-07-30 | 2021-11-05 | 郭福荣 | Traditional Chinese medicine formula for treating gastric ulcer, gastric erosion and helicobacter pylori disease |
| CN114886996A (en) * | 2022-05-13 | 2022-08-12 | 中南民族大学 | Skin-generating oil solution for treating cervicitis through vagina and preparation method and application thereof |
| JP2022146828A (en) * | 2021-03-22 | 2022-10-05 | 均 石井 | Therapeutic agents for gastritis, gastric ulcer, and duodenal ulcer |
| CN115844992A (en) * | 2022-12-09 | 2023-03-28 | 中南民族大学 | External skin-generating oil for preventing and treating eczema and pruritus as well as preparation method and application thereof |
| CN116440194A (en) * | 2023-03-23 | 2023-07-18 | 大连理工大学 | Compound medicine for relieving ulcerative colitis by clysis and application thereof |
| CN117064979A (en) * | 2023-08-02 | 2023-11-17 | 中南民族大学 | External skin care oil for preventing and treating psoriasis and preparation method and application thereof |
-
2023
- 2023-07-12 CN CN202310849834.9A patent/CN116920049B/en active Active
Patent Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464620A (en) * | 1994-07-01 | 1995-11-07 | Zhao; Xinxian | Pharmaceutical composition for treating gastrointestinal disease |
| KR970020114A (en) * | 1995-10-26 | 1997-05-28 | 안봉환 | Anti-ulcer agent containing glutinous rice extract and beverage for preventing ulcer |
| CN103906526A (en) * | 2011-10-25 | 2014-07-02 | 株式会社爱茉莉太平洋 | Wrap fermentation method using medicinal flower, and composition for external application onto the skin using same |
| CN103446488A (en) * | 2012-05-29 | 2013-12-18 | 黄勤 | Drug for protecting gastric mucosa |
| CN102895526A (en) * | 2012-10-31 | 2013-01-30 | 唐和斌 | Externally-applied skin-generating oil for treatment of burn and preparation method and application thereof |
| CN105012702A (en) * | 2015-08-19 | 2015-11-04 | 唐和斌 | Application of externally used skin generation oil in preparation of drugs for preventing or treating diabetic peripheral circulation disturbance and foot ulcer |
| CN105343806A (en) * | 2015-12-17 | 2016-02-24 | 都炳霞 | Traditional Chinese medicine preparation for treating gastritis and gastric ulcer |
| CN106075071A (en) * | 2016-07-27 | 2016-11-09 | 张志杰 | A kind of Chinese medicine composition treating gastric ulcer and duodenal ulcer |
| DE102017131443A1 (en) * | 2017-12-29 | 2019-07-04 | Mingqiu Li | Chinese medicine for the treatment of gastric ulcers |
| CN109078116A (en) * | 2018-10-30 | 2018-12-25 | 黄中杰 | It is a kind of for treating the pure Chinese medicine Sucralfate and preparation method of gastric ulcer |
| CN111298053A (en) * | 2018-11-25 | 2020-06-19 | 佳木斯烧伤专科医院 | Bezoar dragon bone ointment for treating hemorrhoid |
| KR20200099777A (en) * | 2019-02-15 | 2020-08-25 | 상하이 지슈아이 바이오 테크놀로지 컴퍼니 리미티드 | Chinese medicine for gastric ulcer treatment |
| CN109939183A (en) * | 2019-04-03 | 2019-06-28 | 中南民族大学 | A kind of oral skin-generating oil and its preparation method and application for treating oral cavity burn and scald |
| CN109939182A (en) * | 2019-04-03 | 2019-06-28 | 中南民族大学 | A kind of skin-generating oil and its preparation method and application for treating ulcerative colitis |
| JP2022146828A (en) * | 2021-03-22 | 2022-10-05 | 均 石井 | Therapeutic agents for gastritis, gastric ulcer, and duodenal ulcer |
| CN112891437A (en) * | 2021-04-22 | 2021-06-04 | 湘西自然生物科技有限公司 | Traditional Chinese medicine composition for treating gastric ulcer and preparation method thereof |
| CN113599458A (en) * | 2021-07-30 | 2021-11-05 | 郭福荣 | Traditional Chinese medicine formula for treating gastric ulcer, gastric erosion and helicobacter pylori disease |
| CN114886996A (en) * | 2022-05-13 | 2022-08-12 | 中南民族大学 | Skin-generating oil solution for treating cervicitis through vagina and preparation method and application thereof |
| CN115844992A (en) * | 2022-12-09 | 2023-03-28 | 中南民族大学 | External skin-generating oil for preventing and treating eczema and pruritus as well as preparation method and application thereof |
| CN116440194A (en) * | 2023-03-23 | 2023-07-18 | 大连理工大学 | Compound medicine for relieving ulcerative colitis by clysis and application thereof |
| CN117064979A (en) * | 2023-08-02 | 2023-11-17 | 中南民族大学 | External skin care oil for preventing and treating psoriasis and preparation method and application thereof |
Non-Patent Citations (8)
| Title |
|---|
| 易道龙: "消炎生肌膏治皮肤疾患", 四川中医, no. 05, 15 May 1987 (1987-05-15), pages 44 * |
| 朱斌;李娜;陈晴;杨洁;杨阳;: "养胃颗粒对实验性胃溃疡的治疗作用研究", 药学实践杂志, no. 05, 25 September 2018 (2018-09-25), pages 51 - 67 * |
| 田萍;徐坤元;朱向东;邸莎;丁齐又;: "白及的临床应用及其用量探究", 吉林中医药, no. 09, 20 September 2020 (2020-09-20), pages 114 - 117 * |
| 秦美玲;巨晓绒;: "琦美万慈灵软膏治疗溃疡性压疮23例临床观察及护理", 河北中医, vol. 34, no. 09, 28 September 2012 (2012-09-28), pages 1415 - 1416 * |
| 赵福广;赵翠;赵文萱;李超;卞鑫;葛;: "中药组方"胃溃安"对大鼠胃溃疡的治疗作用", 科技视界, no. 05, 15 February 2017 (2017-02-15), pages 84 - 85 * |
| 陈育忠;谢维捷;郝蕾;: "基于文献的胃溃疡中医用药规律研究", 中医药信息, no. 05, 10 September 2013 (2013-09-10), pages 16 - 19 * |
| 韩宇;李鲜;: "中医药治疗胃溃疡的研究进展", 中国中医药现代远程教育, no. 06, 25 March 2016 (2016-03-25), pages 150 - 152 * |
| 麻思萌，等: "平卧菊三七醇提物对溃疡性结肠炎的改善作用", 现代食品科技, vol. 36, no. 2, 20 February 2020 (2020-02-20), pages 12 - 17 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116920049B (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109939182B (en) | Application of skin oil for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis | |
| CN103860591B (en) | A kind of come off for hemorrhoid after the external Miao medicine and preparation method thereof of promoting tissue regeneration and ulcer healing | |
| CN106361993B (en) | Pharmaceutical composition for preventing and treating gastric mucosal injury and preparation method thereof | |
| CN111920908B (en) | Pharmaceutical composition for treating peptic ulcer | |
| CN103520439B (en) | Traditional Chinese medicine for treating heat-toxicity accumulation type chronic osteomyelitis and preparation method thereof | |
| CN116920049B (en) | Skin-care oil for treating gastric ulcer and preparation method and application thereof | |
| CN101890062B (en) | Use of nardostachys chinensis batal and extract thereof in preparation of medicaments for treating gastric ulcer | |
| CN1225254C (en) | Medicinal composition, its preparation process and use in treating psoriasis | |
| CN104095843B (en) | Arctigenin is preparing the application in treating digestive tract ulcer disease medicament | |
| CN107095922A (en) | Children's removing jaundice precious jade medicine bath foam and preparation method thereof | |
| CN113413431A (en) | Traditional Chinese medicine formula for preventing and treating hypertension | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN104147110A (en) | Traditional Chinese medicine formula and compound preparation for treating haemorrhoids | |
| CN108815268A (en) | A kind of external application promotees the Chinese medicine ointment formulation and preparation method thereof of union of wounded skin | |
| CN1180794C (en) | Gallbladder and appendix antiphlogistic | |
| CN116036168B (en) | Traditional Chinese medicine composition for treating phlebitis and application thereof | |
| CN107137640A (en) | Prevent and treat traditional Chinese medicine oral liquid of pet porkling virus diarrhea and preparation method thereof | |
| CN105412325A (en) | Traditional Chinese medicine preparation for treating chronic osteomyelitis as well as preparation method and application of traditional Chinese medicine preparation | |
| CN114652788A (en) | New use of compound dragon's blood | |
| CN102846778B (en) | Chinese medicinal formulation for treating burn and scald and preparation method thereof | |
| CN104740019A (en) | Essential oil for treating recurrent oral ulcer | |
| CN112826857A (en) | Method for preparing pill for treating hemorrhoid and varicosis | |
| CN115998817A (en) | Traditional Chinese medicine stomach-protecting powder for preventing stomach cancer | |
| CN113398225A (en) | Traditional Chinese medicine for alcoholic hepatic fibrosis | |
| CN115364185A (en) | Traditional Chinese medicine tablet for treating gastrectasia by dredging and reducing stomach qi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |